# Healthcare SEC Filings Snapshot: Acquisitions, Delistings, and New Agreements, June 12, 2026

> On June 12, 2026, Rocket Pharmaceuticals disclosed a completed asset acquisition while four smaller healthcare companies filed delisting notices, and three entities, including Climb Bio and Titan Acquisition Corp., entered material definitive agreements. As of June 13, 2026, these filings collectively signal both consolidation activity and continued listing pressure across the healthcare sector.

# Healthcare SEC Filings Snapshot: Acquisitions, Delistings, and New Agreements, June 12, 2026

*As of 2026-06-13. All claims are grounded exclusively in SEC 8-K filings dated 2026-06-12.*

---

## What major transaction did Rocket Pharmaceuticals disclose?

Rocket Pharmaceuticals, Inc. filed an 8-K on June 12, 2026 (Accession No. 0001140361-26-024997) reporting the completion of an acquisition or disposition of assets under Item 2.01, accompanied by a Regulation FD disclosure under Item 7.01. The filing does not specify the counterparty or transaction value within the verified event data, but the completion status confirms the transaction closed on or before the filing date.

**Source:** [SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/0001140361-26-024997-index.htm)

---

## Which healthcare companies received delisting notices on June 12, 2026?

Four companies filed Item 3.01 notices, indicating each received a notice of delisting or failed to satisfy a continued listing rule or standard:

- **Wellgistics Health, Inc.** (Accession No. 0001493152-26-028464)
- **OFA Group** (Accession No. 0001493152-26-028456)
- **Adagio Medical Holdings, Inc.** (Accession No. 0001104659-26-073517)
- **Celularity Inc.** (Accession No. 0001493152-26-028519)

All four filings were made on the same date, June 12, 2026. Item 3.01 filings require disclosure when a company receives formal notice from an exchange regarding noncompliance with listing standards.

**Sources:** [Wellgistics](https://www.sec.gov/Archives/edgar/data/2030763/000149315226028464/0001493152-26-028464-index.htm) | [OFA Group](https://www.sec.gov/Archives/edgar/data/2036307/000149315226028456/0001493152-26-028456-index.htm) | [Adagio Medical](https://www.sec.gov/Archives/edgar/data/2006986/000110465926073517/0001104659-26-073517-index.htm) | [Celularity](https://www.sec.gov/Archives/edgar/data/1752828/000149315226028519/0001493152-26-028519-index.htm)

---

## Which companies entered material definitive agreements?

Three entities disclosed entry into material definitive agreements under Item 1.01 on June 12, 2026:

- **Climb Bio, Inc.** (Accession No. 0001193125-26-269567) filed the largest of the three disclosures at 442 KB and also triggered Item 8.01 (Other Events), suggesting a broader announcement accompanied the agreement.
- **Titan Acquisition Corp.** (Accession No. 0001829126-26-006454) filed under Items 1.01 and 9.01 only.
- **Snow Rothschild Acquisition Corp.** (Accession No. 0001213900-26-068326) filed under Items 1.01 and 3.02, with Item 3.02 indicating unregistered sales of equity securities in connection with the agreement. This filing was the largest at approximately 1 MB.

**Sources:** [Climb Bio](https://www.sec.gov/Archives/edgar/data/1768446/000119312526269567/0001193125-26-269567-index.htm) | [Titan Acquisition Corp.](https://www.sec.gov/Archives/edgar/data/2009183/000182912626006454/0001829126-26-006454-index.htm) | [Snow Rothschild](https://www.sec.gov/Archives/edgar/data/2123475/000121390026068326/0001213900-26-068326-index.htm)

---

## What does this cluster of filings indicate for healthcare investors?

As of June 13, 2026, the simultaneous appearance of four delisting notices on a single trading day reflects ongoing listing compliance stress among smaller healthcare companies. At the same time, Rocket Pharmaceuticals completing an asset transaction and three separate entities entering material agreements on the same date points to continued deal activity in the sector. Investors should consult the full text of each filing for transaction-specific terms, as the verified event data does not include financial details.

---

*All filings sourced from SEC EDGAR. As of 2026-06-13, no subsequent amendments to these filings are reflected in this summary.*

---
Source: MedFuel Intel (https://medfuelintel.com/geo/article/healthcare-sec-filings-snapshot-acquisitions-delistings-and-new-agreements-june--2026-06-13). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.